Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1976 1
1979 1
1980 1
1981 2
1982 2
1983 1
1984 5
1985 2
1986 3
1987 7
1988 12
1989 26
1990 37
1991 51
1992 61
1993 87
1994 96
1995 101
1996 115
1997 117
1998 126
1999 130
2000 155
2001 163
2002 162
2003 206
2004 200
2005 197
2006 214
2007 191
2008 190
2009 160
2010 176
2011 220
2012 185
2013 161
2014 146
2015 151
2016 112
2017 115
2018 133
2019 121
2020 88
2021 104
2022 99
2023 98
2024 91
2025 116
2026 46

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,557 results

Results by year

Filters applied: . Clear all
Page 1
Effects of mind-body exercise on perimenopausal and postmenopausal women: a systematic review and meta-analysis.
Xu H, Liu J, Li P, Liang Y. Xu H, et al. Menopause. 2024 May 1;31(5):457-467. doi: 10.1097/GME.0000000000002336. Menopause. 2024. PMID: 38669625 Free PMC article.
Traditional meta-analysis indicated that mind-body exercise significantly enhanced bone mineral density in perimenopausal and postmenopausal women compared with control groups, with a standardized mean difference (SMD) of 0.41 (95% CI, 0.17 to 0.66; P …
Traditional meta-analysis indicated that mind-body exercise significantly enhanced bone mineral density in perimenopaus …
Shilajit extract reduces oxidative stress, inflammation, and bone loss to dose-dependently preserve bone mineral density in postmenopausal women with osteopenia: A randomized, double-blind, placebo-controlled trial.
Pingali U, Nutalapati C. Pingali U, et al. Phytomedicine. 2022 Oct;105:154334. doi: 10.1016/j.phymed.2022.154334. Epub 2022 Jul 19. Phytomedicine. 2022. PMID: 35933897 Clinical Trial.
Bone mineral density (BMD) of the lumbar spine (LS) and femoral neck (FN) were measured at weeks 0, 24, and 48, and circulating markers of bone turnover (CTX-1, BALP, RANKL, OPG), oxidative stress (MDA, GSH), and inflammation (hsCRP) at weeks 0, 12, 24 …
Bone mineral density (BMD) of the lumbar spine (LS) and femoral neck (FN) were measured at weeks 0, 24, and 48, and cir …
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C; ACTIVE Study Investigators. Miller PD, et al. JAMA. 2016 Aug 16;316(7):722-33. doi: 10.1001/jama.2016.11136. JAMA. 2016. PMID: 27533157 Clinical Trial.
IMPORTANCE: Additional therapies are needed for prevention of osteoporotic fractures. Abaloparatide is a selective activator of the parathyroid hormone type 1 receptor. ...Postmenopausal women with bone mineral density (BMD) T score -2.5 …
IMPORTANCE: Additional therapies are needed for prevention of osteoporotic fractures. Abaloparatide is a selective activator of the p …
Primary Hyperparathyroidism.
Bilezikian JP. Bilezikian JP. J Clin Endocrinol Metab. 2018 Nov 1;103(11):3993-4004. doi: 10.1210/jc.2018-01225. J Clin Endocrinol Metab. 2018. PMID: 30060226 Free PMC article. Review.
The factors that determine which of these clinical presentations is more likely to predominate in a given country include the extent to which biochemical screening is used, vitamin D deficiency is present, and whether parathyroid hormone levels are routinely measured in th …
The factors that determine which of these clinical presentations is more likely to predominate in a given country include the extent to whic …
The role of menopausal hormone therapy in the prevention and treatment of low bone density in perimenopausal and postmenopausal women.
Shah N, Ariel D. Shah N, et al. Curr Opin Obstet Gynecol. 2023 Apr 1;35(2):141-149. doi: 10.1097/GCO.0000000000000858. Epub 2023 Feb 1. Curr Opin Obstet Gynecol. 2023. PMID: 36912327 Review.
PURPOSE OF REVIEW: The purpose of this review is to summarize the evidence on the benefits of menopausal hormone therapy (MHT) for the maintenance of skeletal health, prevention of osteoporosis and related fractures in peri and postmenopausal women. ...SUMMAR …
PURPOSE OF REVIEW: The purpose of this review is to summarize the evidence on the benefits of menopausal hormone therapy (MHT) …
Isoflavone intervention and its impact on bone mineral density in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials.
Inpan R, Na Takuathung M, Sakuludomkan W, Dukaew N, Teekachunhatean S, Koonrungsesomboon N. Inpan R, et al. Osteoporos Int. 2024 Mar;35(3):413-430. doi: 10.1007/s00198-023-06944-y. Epub 2023 Oct 25. Osteoporos Int. 2024. PMID: 37875614
Isoflavones, a type of phytoestrogen, have been suggested to improve bone metabolism and increase bone mass. Therefore, isoflavones are increasingly recognized as a promising natural alternative to hormone replacement therapy for postmenopausal …
Isoflavones, a type of phytoestrogen, have been suggested to improve bone metabolism and increase bone mass. Therefore, isofla …
The efficacy of a comprehensive bone health program in maintaining bone mineral density in postmenopausal women with early-stage breast cancer treated with endocrine therapy: real-world data.
Abdel-Razeq H, Al-Rasheed U, Mashhadani N, Al-Ibraheem A, Abdel-Razeq R, Jaradeh SA, Mansour R, Bater R, Tbayshat S. Abdel-Razeq H, et al. Ir J Med Sci. 2022 Dec;191(6):2511-2515. doi: 10.1007/s11845-021-02897-5. Epub 2022 Jan 28. Ir J Med Sci. 2022. PMID: 35088228
AIMS: In this study, we present real-world data describing the efficacy of implementing a comprehensive bone health program to maintain bone mineral density (BMD) in postmenopausal patients with early-stage breast cancer treated with AI. ...P …
AIMS: In this study, we present real-world data describing the efficacy of implementing a comprehensive bone health program to mainta …
Effects of thyroid-stimulating hormone suppression after thyroidectomy for thyroid cancer on bone mineral density in postmenopausal women: a systematic review and meta-analysis.
Kwak D, Ha J, Won Y, Kwon Y, Park S. Kwak D, et al. BMJ Open. 2021 May 13;11(5):e043007. doi: 10.1136/bmjopen-2020-043007. BMJ Open. 2021. PMID: 33986046 Free PMC article.
OBJECTIVES: We assessed thyroid-stimulating hormone (TSH) suppression effects on bone mineral density (BMD) in postmenopausal women who underwent thyroidectomy. ...RESEARCH DESIGN AND METHODS: Studies evaluating BMD in postmenopausal wome …
OBJECTIVES: We assessed thyroid-stimulating hormone (TSH) suppression effects on bone mineral density (BMD) in …
Threshold based on bone mineral density for therapeutic decision-making in postmenopausal women and men over 50 years old under glucocorticoid therapy.
Brance ML, Larroudé MS, Somma LF, Giacoia E, Diehl M, Galich AM, Ramirez Stieben LA, Maher MC, De La Vega M, Ringer A, Brun LR. Brance ML, et al. Reumatol Clin (Engl Ed). 2023 May;19(5):279-284. doi: 10.1016/j.reumae.2022.10.002. Reumatol Clin (Engl Ed). 2023. PMID: 37147063 Free article.
INTRODUCTION AND AIM: T-score bone mineral density (BMD) thresholds may influence guidance for treatment in patients under glucocorticoid (GC) therapy. ...CONCLUSIONS: With more than 80% agreement of the voting expert panel, a T-score -1.7 was consider …
INTRODUCTION AND AIM: T-score bone mineral density (BMD) thresholds may influence guidance for treatment in patients un …
(99)Tc-MDP maintains bone mineral density for postmenopausal differentiated thyroid cancer patients with osteopenia under thyroid-stimulating hormone suppression.
Zhang Y, Wang Y, Sun D, Ma C. Zhang Y, et al. Front Endocrinol (Lausanne). 2025 Oct 2;16:1657617. doi: 10.3389/fendo.2025.1657617. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 41113720 Free PMC article.
BACKGROUND: The main determinant of skeletal fragility in postmenopausal patients with differentiated thyroid cancer (DTC) and osteopenia is thyroid-stimulating hormone (TSH) suppressive therapy. ...Patients were divided into two groups: calcium/vitamin D sup …
BACKGROUND: The main determinant of skeletal fragility in postmenopausal patients with differentiated thyroid cancer (DTC) and osteop …
4,557 results